Roche Holding AG

03/24/2021 | Press release | Distributed by Public on 03/24/2021 10:37

Chugai: Polivy approved for treatment of relapsed or refractory diffuse large B-cell lymphoma in Japan

Investor Update

Chugai: Polivy approved for treatment of relapsed or refractory diffuse large B-cell lymphoma in Japan

Dear Investor,

Please find attached a press release by Chugai:
https://www.roche.com/dam/jcr:886cf513-18db-4809-a7d5-de8b66ca4b0e/en/210324_IR_Chugai_ePolivy_Approval.pdf

Do not hesitate to contact us for any further questions.

With best regards,

Roche Investor Relations
Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: [email protected]

Jon Kaspar Bayard
Phone: +41 61 68-83894
e-mail: [email protected]
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: [email protected]

Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: [email protected]
Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: [email protected]
Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: [email protected]
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217
e-mail: [email protected]
Dr. Lisa Tuomi
Phone: +1 650 467 8737
e-mail: [email protected]